questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-26 de cytochromes P450
Famille-26 de cytochromes P450 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Attention Deficit and Disruptive Behavior Disorders
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Famille-26 de cytochromes P450 : Questions médicales les plus fréquentes",
"headline": "Famille-26 de cytochromes P450 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Famille-26 de cytochromes P450 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-04",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 enzyme system",
"url": "https://questionsmedicales.fr/mesh/D003577",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 enzyme system",
"code": {
"@type": "MedicalCode",
"code": "D003577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Retinoic acid 4-hydroxylase",
"alternateName": "Retinoic Acid 4-Hydroxylase",
"url": "https://questionsmedicales.fr/mesh/D000072516",
"about": {
"@type": "MedicalCondition",
"name": "Retinoic acid 4-hydroxylase",
"code": {
"@type": "MedicalCode",
"code": "D000072516",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.498.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450",
"alternateName": "Cytochrome P450 Family 26",
"code": {
"@type": "MedicalCode",
"code": "D000072500",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David R Nelson",
"url": "https://questionsmedicales.fr/author/David%20R%20Nelson",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA."
}
},
{
"@type": "Person",
"name": "F Peter Guengerich",
"url": "https://questionsmedicales.fr/author/F%20Peter%20Guengerich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu."
}
},
{
"@type": "Person",
"name": "Donghak Kim",
"url": "https://questionsmedicales.fr/author/Donghak%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
},
{
"@type": "Person",
"name": "Emily E Scott",
"url": "https://questionsmedicales.fr/author/Emily%20E%20Scott",
"affiliation": {
"@type": "Organization",
"name": "Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu."
}
},
{
"@type": "Person",
"name": "Vitchan Kim",
"url": "https://questionsmedicales.fr/author/Vitchan%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Exploring real-time functional magnetic resonance imaging neurofeedback in adolescents with disruptive behavior disorder and callous unemotional traits.",
"datePublished": "2023-10-16",
"url": "https://questionsmedicales.fr/article/37852585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jad.2023.10.036"
}
},
{
"@type": "ScholarlyArticle",
"name": "The conduct and oppositional defiant disorder scales (CODDS) for disruptive behaviour disorders.",
"datePublished": "2022-07-23",
"url": "https://questionsmedicales.fr/article/35961152",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.psychres.2022.114744"
}
},
{
"@type": "ScholarlyArticle",
"name": "Short-Term Impact of \"Amaka Amasanyufu\" Multiple Family Group Intervention on Mental Health Functioning of Children With Disruptive Behavior Disorders in Uganda.",
"datePublished": "2023-03-08",
"url": "https://questionsmedicales.fr/article/36898607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jaac.2022.12.028"
}
},
{
"@type": "ScholarlyArticle",
"name": "Some critical comments on the paper titled \"Some critical considerations in applying the construct of psychopathy to research and classification of childhood disruptive behavior disorders\".",
"datePublished": "2022-10-21",
"url": "https://questionsmedicales.fr/article/36328895",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cpr.2022.102214"
}
},
{
"@type": "ScholarlyArticle",
"name": "Polygenic risk scores for antisocial behavior in relation to amygdala morphology across an attention deficit hyperactivity disorder case-control sample with and without disruptive behavior.",
"datePublished": "2022-07-30",
"url": "https://questionsmedicales.fr/article/35914510",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.euroneuro.2022.07.182"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-26 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072500"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Famille-26 de cytochromes P450 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Famille-26 de cytochromes P450",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Famille-26 de cytochromes P450",
"description": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?\nQuels tests sont utilisés pour évaluer l'activité des CYP26 ?\nLes symptômes cliniques aident-ils au diagnostic ?\nPeut-on utiliser l'imagerie pour le diagnostic ?\nLes antécédents médicaux sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Famille-26 de cytochromes P450",
"description": "Quels sont les symptômes d'une anomalie des CYP26 ?\nLes anomalies des CYP26 causent-elles des douleurs ?\nY a-t-il des symptômes cutanés associés ?\nLes troubles de l'humeur sont-ils liés aux CYP26 ?\nLes anomalies des CYP26 affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Famille-26 de cytochromes P450",
"description": "Comment prévenir les dysfonctionnements des CYP26 ?\nLes tests génétiques peuvent-ils prévenir des problèmes ?\nL'évitement de certains médicaments est-il conseillé ?\nLe suivi médical régulier est-il important ?\nLes habitudes de vie influencent-elles la santé des CYP26 ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Famille-26 de cytochromes P450",
"description": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?\nLes modifications alimentaires aident-elles ?\nDes médicaments spécifiques sont-ils utilisés ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Famille-26 de cytochromes P450",
"description": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?\nLes anomalies des CYP26 peuvent-elles causer des maladies chroniques ?\nY a-t-il un risque accru de cancer ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Famille-26 de cytochromes P450",
"description": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?\nL'âge influence-t-il le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils importants ?\nLes maladies préexistantes augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer les anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des CYP26 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages de métabolites spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les symptômes cliniques aident-ils au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des troubles hormonaux peuvent indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer les CYP26."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux sont-ils importants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de traitement médicamenteux peuvent influencer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une anomalie des CYP26 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes incluent des troubles métaboliques et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 causent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des douleurs liées à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir en raison de déséquilibres métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur sont-ils liés aux CYP26 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de l'humeur peuvent être liés à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 affectent-elles la fertilité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent affecter la fertilité en perturbant les niveaux hormonaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements des CYP26 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un suivi médical régulier peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des problèmes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques avant l'apparition des symptômes."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments est-il conseillé ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les médicaments connus pour interférer avec les CYP26 peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles la santé des CYP26 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines peuvent améliorer la fonction des CYP26."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies hormonales et des ajustements médicamenteux."
}
},
{
"@type": "Question",
"name": "Les modifications alimentaires aident-elles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut soutenir le métabolisme hormonal."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments ciblant les déséquilibres hormonaux peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est encore en recherche pour traiter les anomalies des CYP26."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 peuvent-elles causer des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent augmenter le risque de cancers hormonodépendants."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux et l'exposition à certains médicaments."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de changements hormonaux."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils importants ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut affecter les CYP26."
}
},
{
"@type": "Question",
"name": "Les maladies préexistantes augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies peuvent prédisposer à des anomalies des CYP26."
}
}
]
}
]
}
Adolescents with increased callous unemotional traits (CU traits) in the context of disruptive behavior disorder (DBD) show a persistent pattern of antisocial behavior with shallow affect and a lack o...
In this explorative randomized controlled trial we randomly assigned twenty-seven adolescents with DBD to individualized real-time functional magnetic resonance neurofeedback (rtfMRI-NF) or behavioral...
The rtfMRI-NF (n = 11) and TAU (n = 10) completers showed comparable and significant clinical improvement indicating neither superiority nor inferiority of rtfMRI-NF. The exploratory LMM revealed succ...
This exploratory study demonstrated feasibility and suggests clinical efficacy of individualized rtfMRI-NF comparable to active TAU for adolescents with DBD and increased CU traits. Further studies ar...
This study evaluates the clinical validity of a five-minute instrument, the Conduct and Oppositional Defiant Disorder Scales (CODDS), for assessing oppositional defiant disorder (ODD) and conduct diso...
We evaluate the mid-intervention (8 weeks) and short-term (16 weeks) impact of a culturally adapted multiple family group (MFG) intervention, "Amaka Amasanyufu," on the mental health of children with ...
We analyzed data from the Strengthening mental health and research training in Sub-Saharan Africa (SMART) Africa-Uganda study. Schools were randomized to the following: a control group; an MFG facilit...
There were significant group-by-time interactions for all outcomes, and differences were observed mid-intervention, with short-term effects at 16 weeks (end-intervention). MFG-PP and MFG-CHW children ...
Amaka Amasanyufu MFG intervention is effective for reducing depressive symptoms and improving self-concept among children with DBDs while reducing parental stress and mental health problems among care...
SMART Africa (Strengthening Mental Health Research and Training); https://clinicaltrials.gov/: NCT03081195....
Frick (2022) presented a narrative review of some literature and made several critical comments regarding the extension of the full psychopathy construct to research and classification of childhood di...
Antisocial and aggressive behaviors show considerable heritability and are central to disruptive behavior disorders (DBDs), but are also frequently observed in attention deficit hyperactivity disorder...
Previous research has found some peculiarities in sexual functioning of adults with attention deficit/hyperactivity disorder (ADHD). Using a set of questionnaires that had to be answered online, we as...
Attention-deficit/hyperactivity disorder (ADHD; also known as hyperkinetic disorder) is a common neurodevelopmental condition that affects children and adults worldwide. ADHD has a predominantly genet...
This study aimed to investigate social cognition and empathy properties in children among Disruptive Mood Dysregulation Disorder (DMDD) + Attention and Hyperactivity Disorder(ADHD); ADHD and healthy c...
Twenty-two children with DMDD were compared to matched 30 children with ADHD and 60 healthy controls. We administered Affective Reactivity Index (ARI), KaSi Empathy Scale, Kiddie-SADS, and Reading Min...
DMDD + ADHD group had lower performance in ToM skills and empathy than in two groups. The ARI scores were found to be statistically significantly higher in the DMDD group than in two groups. It was al...
These results might be important to understand the difficulties in social functioning and interpersonal relationship in children with DMDD and ADHD. Children with DMDD may attend specific therapeutic ...
The current study sought to examine whether psycholinguistic assessments could discriminate children and adolescents with developmental language disorder (DLD) from those with attention-deficit/hypera...
The Clinical Evaluation of Language Fundamentals-Screening Test (CELFST; Wiig et al., 2013), the Comprehensive Test of Phonological Processing (...
The presence of a language disorder (with or without ADHD) predicted poor performance across tasks. Children and adolescents with ADHD (combined vs. inattentive) only significantly differed in sight w...
The combination of comorbid ADHD + DLD did not appear to be associated with lower language abilities, sight word reading, or phonemic decoding relative to DLD alone. Reading efficiency was effective i...
To evaluate the prevalence and types of sleep problems and their correlations with melatonin content and behavior in Attention-Deficit Hyperactivity Disorder (ADHD) children....
Sleep in ADHD children and typically developing children (TD) aged 6-14 was assessed by the Sleep Disorders Scale for Children (SDSC) and actigraphy, salivary melatonin quantified by ELISA, and behavi...
ADHD children showed a higher frequency of sleep disturbances, higher sleep latency, and lower sleep efficiency than in the TD group. The ADHD group presented lower melatonin nocturnal content compare...
This study provides, for the first time, evidence that among the frequent sleep disturbances in ADHD, the disorders in initiating and maintaining sleep are associated with the low levels of melatonin ...